Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2The Following Huge Thing: 5 Progressive Tech New businesses
- 3Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 4A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- 5Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- Independence from the rat race: How to Save and Contribute Shrewdly
- In vogue Sleepwear Patterns for 2024
- Farmers call for French blockades over cow disease cull
- The 10 Most Significant Games in History
